The heparanase/syndecan-1 axis in cancer: Mechanisms and therapies

FEBS Journal

Volumn 280, Issue 10, 2013, Pages 2294-2306

  Ramani, Vishnu C ^a   Purushothaman, Anurag ^a,b   Stewart, Mark D ^a   Thompson, Camilla A ^a   Vlodavsky, Israel ^c   Au, Jessie L S ^d   Sanderson, Ralph D ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d Optimum Energy LLC   (United States)

Author keywords

extracellular signal regulated kinase; heparan sulfate; heparanase; heparin mimics; hepatocyte growth factor; syndecan 1; vascular endothelial growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; GELATINASE B; GEMCITABINE; GLYCOSAMINOGLYCAN; HEPARANASE; M 402; PG 545; PI 88; PROTEIN KINASE C; SCATTER FACTOR; SST 0001; SYNDECAN 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; BLEEDING; BREAST CANCER; BREAST CARCINOMA; BREAST METASTASIS; CANCER INHIBITION; CANCER PROGNOSIS; CELL SURFACE; COLON CANCER; EWING SARCOMA; EXOSOME; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; INJECTION SITE BLEEDING; INJECTION SITE REACTION; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; METASTASIS INHIBITION; MULTIPLE MYELOMA; MYELOMA; NEOPLASM; NONHUMAN; PANCREAS CANCER; PANCREAS METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; THROMBOSIS; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMIMETIC MATERIALS; CELL NUCLEUS; ENZYME ACTIVATION; ENZYME INHIBITORS; EXOSOMES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONIDASE; HEPARITIN SULFATE; HEPATOCYTE GROWTH FACTOR; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; SYNDECAN-1;

EID: 84877694957     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12168     Document Type: Review

References (115)

1. Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, &, Vlodavsky I, (2010) Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J 277, 3890-3903.
2. Arvatz G, Shafat I, Levy-Adam F, Ilan N, &, Vlodavsky I, (2011) The heparanase system and tumor metastasis: is heparanase the seed and soil? Cancer Metastasis Rev 30, 253-268.
3. Vlodavsky I, Elkin M, Abboud-Jarrous G, Levi-Adam F, Fuks L, Shafat I, &, Ilan N, (2008) Heparanase: one molecule with multiple functions in cancer progression. Connect Tissue Res 49, 207-210.
4. Ilan N, Elkin M, &, Vlodavsky I, (2006) Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 38, 2018-2039. (Pubitemid 44397619)
5. Purushothaman A, Babitz SK, &, Sanderson RD, (2012) Heparanase enhances the insulin receptor signaling pathway to activate ERK in multiple myeloma. J Biol Chem 287, 41288-41296.
6. Purushothaman A, Chen L, Yang Y, &, Sanderson RD, (2008) Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem 283, 32628-32636.
7. Ridgway LD, Wetzel MD, &, Marchetti D, (2011) Heparanase modulates Shh and Wnt3a signaling in human medulloblastoma cells. Exp Ther Med 2, 229-238.
8. Ridgway LD, Wetzel MD, Ngo JA, Erdreich-Epstein A, &, Marchetti D, (2012) Heparanase-induced GEF-H1 signaling regulates the cytoskeletal dynamics of brain metastatic breast cancer cells. Mol Cancer Res 10, 689-702.
9. Ma P, Beck SL, Raab RW, McKown RL, Coffman GL, Utani A, Chirico WJ, Rapraeger AC, &, Laurie GW, (2006) Heparanase deglycanation of syndecan-1 is required for binding of the epithelial-restricted prosecretory mitogen lacritin. J Cell Biol 174, 1097-1106. (Pubitemid 44455196)
10. Neuss S, Becher E, Woltje M, Tietze L, &, Jahnen-Dechent W, (2004) Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Stem Cells 22, 405-414. (Pubitemid 38736624)
11. Nakamura T, Sakai K, &, Matsumoto K, (2011) Hepatocyte growth factor twenty years on: much more than a growth factor. J Gastroenterol Hepatol 26, 188-202.
12. Birchmeier C, Birchmeier W, Gherardi E, &, Vande Woude GF, (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4, 915-925. (Pubitemid 37493640)
13. You WK, &, McDonald DM, (2008) The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep 41, 833-839.
14. Lesko E, &, Majka M, (2008) The biological role of HGF-MET axis in tumor growth and development of metastasis. Front Biosci 13, 1271-1280. (Pubitemid 351594710)
15. Borset M, Hjorth-Hansen H, Seidel C, Sundan A, &, Waage A, (1996) Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 88, 3998-4004. (Pubitemid 26383124)
16. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, et al,. (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99, 1745-1757. (Pubitemid 34533050)
17. Derksen PW, de Gorter DJ, Meijer HP, Bende RJ, van Dijk M, Lokhorst HM, Bloem AC, Spaargaren M, &, Pals ST, (2003) The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 17, 764-774. (Pubitemid 36519374)
18. Holt RU, Baykov V, Ro TB, Brabrand S, Waage A, Sundan A, &, Borset M, (2005) Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor. Haematologica 90, 479-488. (Pubitemid 40592890)
19. Hjertner O, Torgersen ML, Seidel C, Hjorth-Hansen H, Waage A, Borset M, &, Sundan A, (1999) Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease. Blood 94, 3883-3888.
20. Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A, &, Waage A, (1998) Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 91, 806-812. (Pubitemid 28078282)
21. Ramani VC, Yang Y, Ren Y, Nan L, &, Sanderson RD, (2011) Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J Biol Chem 286, 6490-6499.
22. Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, &, Pals ST, (2002) Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 99, 1405-1410. (Pubitemid 34547098)
23. Deakin JA, &, Lyon M, (1999) Differential regulation of hepatocyte growth factor/scatter factor by cell surface proteoglycans and free glycosaminoglycan chains. J Cell Sci 112, 1999-2009. (Pubitemid 29338824)
24. Seidel C, Borset M, Hjertner O, Cao D, Abildgaard N, Hjorth-Hansen H, Sanderson RD, Waage A, &, Sundan A, (2000) High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood 96, 3139-3146.
25. Cohen-Kaplan V, Naroditsky I, Zetser A, Ilan N, Vlodavsky I, &, Doweck I, (2008) Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer 123, 2566-2573.
26. Purushothaman A, Uyama T, Kobayashi F, Yamada S, Sugahara K, Rapraeger AC, &, Sanderson RD, (2010) Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 115, 2449-2457.
27. Brooks PC, Clark RA, &, Cheresh DA, (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264, 569-571.
28. Mahabeleshwar GH, Feng W, Reddy K, Plow EF, &, Byzova TV, (2007) Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ Res 101, 570-580. (Pubitemid 351325874)
29. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, &, Zako M, (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68, 729-777. (Pubitemid 29449208)
30. Fitzgerald ML, Wang Z, Park PW, Murphy G, &, Bernfield M, (2000) Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 148, 811-824.
31. Manon-Jensen T, Itoh Y, &, Couchman JR, (2010) Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J 277, 3876-3889.
32. Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Owens RB, &, Wilson CS, (2001) Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol 14, 1052-1058. (Pubitemid 32976795)
33. Hayashida K, Bartlett AH, Chen Y, &, Park PW, (2010) Molecular and cellular mechanisms of ectodomain shedding. Anat Rec 293, 925-937.
34. Reiland J, Ott VL, Lebakken CS, Yeaman C, McCarthy J, &, Rapraeger AC, (1996) Pervanadate activation of intracellular kinases leads to tyrosine phosphorylation and shedding of syndecan-1. Biochem J 319, 39-47. (Pubitemid 26394737)
35. Hayashida K, Stahl PD, &, Park PW, (2008) Syndecan-1 ectodomain shedding is regulated by the small GTPase Rab5. J Biol Chem 283, 35435-35444.
36. Ramani VC, Pruett PS, Thompson CA, DeLucas LD, &, Sanderson RD, (2012) Heparan sulfate chains of syndecan-1 regulate ectodomain shedding. J Biol Chem 287, 9952-9961.
37. Yang Y, Macleod V, Miao HQ, Theus A, Zhan F, Shaughnessy JD Jr, Sawyer J, Li JP, Zcharia E, Vlodavsky I, et al,. (2007) Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 282, 13326-13333. (Pubitemid 47100527)
38. Sanderson RD, &, Couchman JR, (2012) Targeting syndecan shedding in cancer. In Extracellular Matrix: Pathobiology and Signaling (, Karamanos NK, ed.), pp. 802-812. De Gruyter, Berlin, Germany.
39. Choi S, Lee H, Choi JR, &, Oh ES, (2010) Shedding; towards a new paradigm of syndecan function in cancer. BMB Rep 43, 305-310.
40. Joensuu H, Anttonen A, Eriksson M, Makitaro R, Alfthan H, Kinnula V, &, Leppa S, (2002) Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res 62, 5210-5217. (Pubitemid 35024592)
41. Vassilakopoulos TP, Kyrtsonis MC, Papadogiannis A, Nadali G, Angelopoulou MK, Tzenou T, Dimopoulou MN, Siakantaris MP, Kontopidou FN, Kalpadakis C, et al,. (2005) Serum levels of soluble syndecan-1 in Hodgkin's lymphoma. Anticancer Res 25, 4743-4746. (Pubitemid 41729540)
42. Dhodapkar MV, Kelly T, Theus A, Athota AB, Barlogie B, &, Sanderson RD, (1997) Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br J Haematol 99, 368-371. (Pubitemid 27497569)
43. Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, Abildgaard N, Waage A, &, Borset M, (2000) Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95, 388-392. (Pubitemid 30041645)
44. Lovell R, Dunn JA, Begum G, Barth NJ, Plant T, Moss PA, Drayson MT, &, Pratt G, (2005) Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival. Br J Haematol 130, 542-548. (Pubitemid 43899757)
45. Dhodapkar MV, Abe E, Theus A, Lacy M, Langford JK, Barlogie B, &, Sanderson RD, (1998) Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood 91, 2679-2688. (Pubitemid 28227516)
46. Su G, Blaine SA, Qiao D, &, Friedl A, (2008) Membrane type 1 matrix metalloproteinase-mediated stromal syndecan-1 shedding stimulates breast carcinoma cell proliferation. Cancer Res 68, 9558-9565.
47. Stanley MJ, Stanley MW, Sanderson RD, &, Zera R, (1999) Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am J Clin Pathol 112, 377-383. (Pubitemid 30214778)
48. Su G, Blaine SA, Qiao D, &, Friedl A, (2007) Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation. J Biol Chem 282, 14906-14915. (Pubitemid 47093352)
49. Nikolova V, Koo CY, Ibrahim SA, Wang Z, Spillmann D, Dreier R, Kelsch R, Fischgrabe J, Smollich M, Rossi LH, et al,. (2009) Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 30, 397-407.
50. Aragao AZ, Belloni M, Simabuco FM, Zanetti MR, Yokoo S, Domingues RR, Kawahara R, Pauletti BA, Goncalves A, Agostini M, et al,. (2012) Novel processed form of syndecan-1 shed from SCC-9 cells plays a role in cell migration. PLoS One 7, e43521.
51. Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A, Epstein J, &, Sanderson RD, (2002) Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 100, 610-617. (Pubitemid 34761126)
52. Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E, Pantesco V, Baudard M, De Vos J, Larroque M, et al,. (2007) Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 109, 4914-4923. (Pubitemid 46827789)
53. Sotnikov I, Hershkoviz R, Grabovsky V, Ilan N, Cahalon L, Vlodavsky I, Alon R, &, Lider O, (2004) Enzymatically quiescent heparanase augments T cell interactions with VCAM-1 and extracellular matrix components under versatile dynamic contexts. J Immunol 172, 5185-5193. (Pubitemid 38542014)
54. Levy-Adam F, Feld S, Suss-Toby E, Vlodavsky I, &, Ilan N, (2008) Heparanase facilitates cell adhesion and spreading by clustering of cell surface heparan sulfate proteoglycans. PLoS One 3, e2319.
55. Reiland J, Kempf D, Roy M, Denkins Y, &, Marchetti D, (2006) FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells. Neoplasia 8, 596-606. (Pubitemid 44061315)
56. Kato M, Wang H, Kainulainen V, Fitzgerald ML, Ledbetter S, Ornitz DM, &, Bernfield M, (1998) Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 4, 691-697. (Pubitemid 28274669)
57. Liu D, Shriver Z, Venkataraman G, El Shabrawi Y, &, Sasisekharan R, (2002) Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc Natl Acad Sci USA 99, 568-573. (Pubitemid 34106552)
58. Masola V, Gambaro G, Tibaldi E, Brunati AM, Gastaldello A, D'Angelo A, Onisto M, &, Lupo A, (2012) Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells. J Biol Chem 287, 1478-1488.
59. Yang Y, Borset M, Langford JK, &, Sanderson RD, (2003) Heparan sulfate regulates targeting of syndecan-1 to a functional domain on the cell surface. J Biol Chem 278, 12888-12893. (Pubitemid 36800053)
60. Mertens G, Van der Schueren B, van den Berghe H, &, David G, (1996) Heparan sulfate expression in polarized epithelial cells: the apical sorting of glypican (GPI-anchored proteoglycan) is inversely related to its heparan sulfate content. J Cell Biol 132, 487-497. (Pubitemid 26053449)
61. Schubert SY, Ilan N, Shushy M, Ben-Izhak O, Vlodavsky I, &, Goldshmidt O, (2004) Human heparanase nuclear localization and enzymatic activity. Lab Invest 84, 535-544. (Pubitemid 38858462)
62. Kobayashi M, Naomoto Y, Nobuhisa T, Okawa T, Takaoka M, Shirakawa Y, Yamatsuji T, Matsuoka J, Mizushima T, Matsuura H, et al,. (2006) Heparanase regulates esophageal keratinocyte differentiation through nuclear translocation and heparan sulfate cleavage. Differentiation 74, 235-243. (Pubitemid 43801422)
63. Zhang L, Sullivan P, Suyama J, &, Marchetti D, (2010) Epidermal growth factor-induced heparanase nucleolar localization augments DNA topoisomerase I activity in brain metastatic breast cancer. Mol Cancer Res 8, 278-290.
64. He YQ, Sutcliffe EL, Bunting KL, Li J, Goodall KJ, Poon IK, Hulett MD, Freeman C, Zafar A, McInnes RL, et al,. (2012) The endoglycosidase heparanase enters the nucleus of T lymphocytes and modulates H3 methylation at actively transcribed genes via the interplay with key chromatin modifying enzymes. Transcription 3, 130-145.
65. Doweck I, Kaplan-Cohen V, Naroditsky I, Sabo E, Ilan N, &, Vlodavsky I, (2006) Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia 8, 1055-1061. (Pubitemid 44936155)
66. Ohkawa T, Naomoto Y, Takaoka M, Nobuhisa T, Noma K, Motoki T, Murata T, Uetsuka H, Kobayashi M, Shirakawa Y, et al,. (2004) Localization of heparanase in esophageal cancer cells: respective roles in prognosis and differentiation. Lab Invest 84, 1289-1304. (Pubitemid 40063695)
67. Takaoka M, Naomoto Y, Ohkawa T, Uetsuka H, Shirakawa Y, Uno F, Fujiwara T, Gunduz M, Nagatsuka H, Nakajima M, et al,. (2003) Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest 83, 613-622. (Pubitemid 36618040)
68. Ishihara M, Fedarko NS, &, Conrad HE, (1986) Transport of heparan sulfate into the nuclei of hepatocytes. J Biol Chem 261, 13575-13580. (Pubitemid 17196377)
69. Richardson TP, Trinkaus-Randall V, &, Nugent MA, (2001) Regulation of heparan sulfate proteoglycan nuclear localization by fibronectin. J Cell Sci 114, 1613-1623. (Pubitemid 32454660)
70. Brockstedt U, Dobra K, Nurminen M, &, Hjerpe A, (2002) Immunoreactivity to cell surface syndecans in cytoplasm and nucleus: tubulin-dependent rearrangements. Exp Cell Res 274, 235-245. (Pubitemid 34946965)
71. Hsia E, Richardson TP, &, Nugent MA, (2003) Nuclear localization of basic fibroblast growth factor is mediated by heparan sulfate proteoglycans through protein kinase C signaling. J Cell Biochem 88, 1214-1225. (Pubitemid 36397459)
72. Buczek-Thomas JA, Hsia E, Rich CB, Foster JA, &, Nugent MA, (2008) Inhibition of histone acetyltransferase by glycosaminoglycans. J Cell Biochem 105, 108-120.
73. Nilsson U, Johnsson R, Fransson LA, Ellervik U, &, Mani K, (2010) Attenuation of tumor growth by formation of antiproliferative glycosaminoglycans correlates with low acetylation of histone H3. Cancer Res 70, 3771-3779.
74. Chen L, &, Sanderson RD, (2009) Heparanase regulates levels of syndecan-1 in the nucleus. PLoS One 4, e4947.
75. Tumova S, Hatch BA, Law DJ, &, Bame KJ, (1999) Basic fibroblast growth factor does not prevent heparan sulphate proteoglycan catabolism in intact cells, but it alters the distribution of the glycosaminoglycan degradation products. Biochem J 337, 471-481.
76. Zong F, Fthenou E, Wolmer N, Hollosi P, Kovalszky I, Szilak L, Mogler C, Nilsonne G, Tzanakakis G, &, Dobra K, (2009) Syndecan-1 and FGF-2, but not FGF receptor-1, share a common transport route and co-localize with heparanase in the nuclei of mesenchymal tumor cells. PLoS One 4, e7346.
77. Purushothaman A, Hurst DR, Pisano C, Mizumoto S, Sugahara K, &, Sanderson RD, (2011) Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J Biol Chem 286, 30377-30383.
78. Record M, Subra C, Silvente-Poirot S, &, Poirot M, (2011) Exosomes as intercellular signalosomes and pharmacological effectors. Biochem Pharmacol 81, 1171-1182.
79. Ge R, Tan E, Sharghi-Namini S, &, Asada HH, (2012) Exosomes in cancer microenvironment and beyond: have we overlooked these extracellular messengers? Cancer Microenviron 5, 323-332.
80. Bobrie A, Colombo M, Raposo G, &, Thery C, (2011) Exosome secretion: molecular mechanisms and roles in immune responses. Traffic 12, 1659-1668.
81. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J, &, Ratajczak MZ, (2005) Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 113, 752-760. (Pubitemid 40101256)
82. Peinado H, Lavotshkin S, &, Lyden D, (2011) The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol 21, 139-146.
83. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, Garcia-Santos G, Ghajar C, et al,. (2012) Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18, 883-891.
84. Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A, Ivarsson Y, Depoortere F, Coomans C, Vermeiren E, et al,. (2012) Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat Cell Biol 14, 677-685.
85. Keller S, Konig AK, Marme F, Runz S, Wolterink S, Koensgen D, Mustea A, Sehouli J, &, Altevogt P, (2009) Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes. Cancer Lett 278, 73-81.
86. Casu B, Vlodavsky I, &, Sanderson RD, (2008) Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb 36, 195-203.
87. Coombe DR, &, Kett WC, (2012) Heparin mimetics. Handb Exp Pharmacol 207, 361-383.
88. Cochran S, Li C, Fairweather JK, Kett WC, Coombe DR, &, Ferro V, (2003) Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance. J Med Chem 46, 4601-4608. (Pubitemid 37238760)
89. Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW, Mok KT, Lee WC, Yeh HZ, Ho MC, et al,. (2009) Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 50, 958-968.
90. Dredge K, Hammond E, Handley P, Gonda TJ, Smith MT, Vincent C, Brandt R, Ferro V, &, Bytheway I, (2011) PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer 104, 635-642.
91. Ferro V, Liu L, Johnstone KD, Wimmer N, Karoli T, Handley P, Rowley J, Dredge K, Li CP, Hammond E, et al,. (2012) Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis. J Med Chem 55, 3804-3813.
92. Hammond E, Brandt R, &, Dredge K, (2012) PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model. PLoS One 7, e52175.
93. Naggi A, Casu B, Perez M, Torri G, Cassinelli G, Penco S, Pisano C, Giannini G, Ishai-Michaeli R, &, Vlodavsky I, (2005) Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem 280, 12103-12113.
94. Shafat I, Ben-Arush MW, Issakov J, Meller I, Naroditsky I, Tortoteto M, Cassinelli G, Lanzi C, Pisano C, Ilan N, et al,. (2011) Preclinical and clinical significance of heparanase in Ewing's sarcoma. J Cell Mol Med 15, 1857-1864.
95. Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, Sasisekharan R, Naggi A, Torri G, Casu B, et al,. (2007) The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 110, 2041-2048. (Pubitemid 47443921)
96. Ritchie JP, Ramani VC, Ren Y, Naggi A, Torri G, Casu B, Penco S, Pisano C, Carminati P, Tortoreto M, et al,. (2011) SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res 17, 1382-1393.
97. Meirovitz A, Hermano E, Lerner I, Zcharia E, Pisano C, Peretz T, &, Elkin M, (2011) Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma. Cancer Res 71, 2772-2780.
98. Zhou H, Roy S, Cochran E, Zouaoui R, Chu CL, Duffner J, Zhao G, Smith S, Galcheva-Gargova Z, Karlgren J, et al,. (2011) M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS One 6, e21106.
99. Schmidt EP, Yang Y, Janssen WJ, Gandjeva A, Perez MJ, Barthel L, Zemans RL, Bowman JC, Koyanagi DE, Yunt ZX, et al,. (2012) The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat Med 18, 1217-1223.
100. Ziolkowski AF, Popp SK, Freeman C, Parish CR, &, Simeonovic CJ, (2012) Heparan sulfate and heparanase play key roles in mouse beta cell survival and autoimmune diabetes. J Clin Invest 122, 132-141.
101. Gil N, Goldberg R, Neuman T, Garsen M, Zcharia E, Rubinstein AM, van Kuppevelt T, Meirovitz A, Pisano C, Li JP, et al,. (2012) Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes 61, 208-216.
102. Tsuzuki Y, Nguyen TK, Garud DR, Kuberan B, &, Koketsu M, (2010) 4-deoxy-4-fluoro-xyloside derivatives as inhibitors of glycosaminoglycan biosynthesis. Bioorg Med Chem Lett 20, 7269-7273.
103. Fritz TA, Lugemwa FN, Sarkar AK, &, Esko JD, (1994) Biosynthesis of heparan sulfate on ß-D-xylosides depends on aglycone structure. J Biol Chem 269, 300-307. (Pubitemid 24026659)
104. Beauvais DM, Ell BJ, McWhorter AR, &, Rapraeger AC, (2009) Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J Exp Med 206, 691-705.
105. Beauvais DM, &, Rapraeger AC, (2010) Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation. J Cell Sci 123, 3796-3807.
106. Zhang L, Sullivan PS, Goodman JC, Gunaratne PH, &, Marchetti D, (2011) MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res 71, 645-654.
107. Welton JL, Khanna S, Giles PJ, Brennan P, Brewis IA, Staffurth J, Mason MD, &, Clayton A, (2010) Proteomics analysis of bladder cancer exosomes. Mol Cell Proteomics 9, 1324-1338.
108. Choi DS, Lee JM, Park GW, Lim HW, Bang JY, Kim YK, Kwon KH, Kwon HJ, Kim KP, &, Gho YS, (2007) Proteomic analysis of microvesicles derived from human colorectal cancer cells. J Proteome Res 6, 4646-4655.
109. Gonzales PA, Pisitkun T, Hoffert JD, Tchapyjnikov D, Star RA, Kleta R, Wang NS, &, Knepper MA, (2009) Large-scale proteomics and phosphoproteomics of urinary exosomes. J Am Soc Nephrol 20, 363-379.
110. Mathivanan S, Lim JW, Tauro BJ, Ji H, Moritz RL, &, Simpson RJ, (2010) Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature. Mol Cell Proteomics 9, 197-208.
111. Gonzalez-Begne M, Lu B, Han X, Hagen FK, Hand AR, Melvin JE, &, Yates JR, (2009) Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT). J Proteome Res 8, 1304-1314.
112. Carayon K, Chaoui K, Ronzier E, Lazar I, Bertrand-Michel J, Roques V, Balor S, Terce F, Lopez A, Salome L, et al,. (2011) Proteolipidic composition of exosomes changes during reticulocyte maturation. J Biol Chem 286, 34426-34439.
113. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, &, Lotvall JO, (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9, 654-659. (Pubitemid 47214727)
114. Ji H, Erfani N, Tauro BJ, Kapp EA, Zhu HJ, Moritz RL, Lim JW, &, Simpson RJ, (2008) Difference gel electrophoresis analysis of Ras-transformed fibroblast cell-derived exosomes. Electrophoresis 29, 2660-2671. (Pubitemid 351911894)
115. Thompson CA, Purushothaman A, Ramani VC, Vlodavsky I, &, Sanderson RD, (2013) Heparanase regulates secretion, composition and function of tumor cell-derived exosomes. J Biol Chem, doi: 10.1074/jbc.C112.444562.